Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05504837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Assessing KB407 for the Treatment of Cystic Fibrosis

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 12 to 20v9 Show 6 more changesShow less
    • Primary completion date: Dec 2025 to Dec 2026
    • Study sites: 5 to 6
    • Study completion date: Jan 2026 to Mar 2027
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study arms: 3 to 4
  2. Study sites: 3 to 5
    • Primary completion date: Jun 2025 to Dec 2025
    • Study completion date: Jul 2025 to Jan 2026
    • Eligibility criteria revised
    v8
  3. Primary completion date: Jul 2024 to Jun 2025
    • Study sites: 2 to 3
    • Study completion date: Jul 2024 to Jul 2025
    v7
  4. 2 versions Re-verified since Aug 15, 2023, no change to tracked fieldsv5-v6
  5. Enrollment target: 20 to 12
    • Primary and study completion dates: Mar 2024 to Jul 2024
    • Start date changed from estimate of Jun 2023 to Jun 30, 2023
    • Eligibility criteria shortened, about 30 words
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 2022 to Jun 2023
    • Study sites: 1 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Trial Details
NCT Number NCT05504837
Lead Sponsor Krystal Biotech, Inc.
Conditions
(from sponsor)		 Cystic Fibrosis
Related terms Cystic Fibrosis
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov